

Laura Turunen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7311894/publications.pdf>

Version: 2024-02-01

17
papers

781
citations

840776

11
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

1705
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	9.4	334
2	Methods for High-throughput Drug Combination Screening and Synergy Scoring. <i>Methods in Molecular Biology</i> , 2018, 1711, 351-398.	0.9	140
3	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	9.4	73
4	Automated Panning and Screening Procedure on Microplates for Antibody Generation from Phage Display Libraries. <i>Journal of Biomolecular Screening</i> , 2009, 14, 282-293.	2.6	55
5	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. <i>Viruses</i> , 2017, 9, 271.	3.3	39
6	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, .	10.3	28
7	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. <i>Chemistry and Biology</i> , 2015, 22, 1144-1155.	6.0	22
8	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. <i>Journal of the Association for Laboratory Automation</i> , 2016, 21, 27-36.	2.8	22
9	Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. <i>Cancers</i> , 2020, 12, 92.	3.7	20
10	Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells. <i>Journal of Neuroscience Methods</i> , 2014, 222, 142-146.	2.5	17
11	A Structural Insight into the Molecular Recognition of a (Δ^9)-THC-Tetrahydrocannabinol and the Development of a Sensitive, One-Step, Homogeneous Immunocomplex-Based Assay for Its Detection. <i>Journal of Molecular Biology</i> , 2010, 400, 803-814.	4.2	12
12	iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. <i>Pharmacological Research</i> , 2022, 175, 105996.	7.1	11
13	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 14755.	3.3	7
14	Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer. <i>Clinical Epigenetics</i> , 2019, 11, 192.	4.1	1
15	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	1.4	0
16	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	1.4	0
17	Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations. <i>Blood</i> , 2018, 132, 2743-2743.	1.4	0